Payment overview · 2025
General Payments
$275.82
14 reported records · 10 companies
Healthcare provider profile · identity verified
Alexander Hernandez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1144725946
Verified facts
What the public records show
CMS Open Payments records show Alexander Hernandez, M.D. received $275.82 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.37 | 21.9% | 3 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $49.77 | 18.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.88 | 13.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.63 | 8.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.22 | 8.8% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $20.48 | 7.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.47 | 6.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.61 | 5.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.40 | 5.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $11.99 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $275.82 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $49.77 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $11.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 56 |
| Lisinopril | Lisinopril | 172 | 45 |
| Omeprazole | Omeprazole | 166 | 55 |
| Gabapentin | Gabapentin | 132 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 46 |
| Metformin Hcl | Metformin Hcl | 109 | 29 |
| Carvedilol | Carvedilol | 92 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 29 |
| Losartan Potassium | Losartan Potassium | 78 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 20 |
| Jardiance | Empagliflozin | 70 | 21 |
| Sertraline Hcl | Sertraline Hcl | 70 | 18 |
| Tramadol Hcl | Tramadol Hcl | 67 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 21 |
| Allopurinol | Allopurinol | 64 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 23 |
| Meloxicam | Meloxicam | 61 | 25 |
| Trazodone Hcl | Trazodone Hcl | 57 | 27 |
| Potassium Chloride | Potassium Chloride | 53 | 18 |
| Simvastatin | Simvastatin | 47 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 18 |
| Ondansetron Odt | Ondansetron | 44 | 14 |
| Ozempic | Semaglutide | 44 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 15 |
| Famotidine | Famotidine | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Furosemide | Furosemide | 38 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 14 |
| Buspirone Hcl | Buspirone Hcl | 35 | 12 |
| Montelukast Sodium | Montelukast Sodium | 35 | 13 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Azithromycin | Azithromycin | 30 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 14 |
| Glipizide | Glipizide | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Ramipril | Ramipril | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humira | Adalimumab | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $275.82 · 14 records | Novo Nordisk Inc | APTIMA, Axonics, CAPVAXIVE, Dexcom G6 Transmitter, Dojolvi, ELIQUIS, GARDASIL 9, LEQVIO, NURTEC ODT, Ozempic, ROTATEQ, Rybelsus, TZIELD, UROLIFT, VAXNEUVANCE, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error